1. Home
  2. SCZM vs CDNA Comparison

SCZM vs CDNA Comparison

Compare SCZM & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SCZM

Santacruz Silver Mining Ltd. Common Shares

N/A

Current Price

$9.99

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$17.91

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCZM
CDNA
Founded
N/A
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
SCZM
CDNA
Price
$9.99
$17.91
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$27.33
AVG Volume (30 Days)
396.0K
617.8K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$48,324,000.00
Revenue This Year
$22.30
$15.37
Revenue Next Year
$69.17
$11.23
P/E Ratio
$14.27
N/A
Revenue Growth
N/A
18.93
52 Week Low
$8.92
$10.96
52 Week High
$17.65
$21.49

Technical Indicators

Market Signals
Indicator
SCZM
CDNA
Relative Strength Index (RSI) 36.32 38.95
Support Level $8.92 $16.74
Resistance Level $12.81 $18.02
Average True Range (ATR) 0.74 0.86
MACD 0.01 -0.10
Stochastic Oscillator 29.18 28.10

Price Performance

Historical Comparison
SCZM
CDNA

About SCZM Santacruz Silver Mining Ltd. Common Shares

Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapan, and Corporate and Other activities. Key revenue is generated from Zimapan.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: